Navigation Links
PRA Opens Office in Singapore
Date:2/23/2012

RALEIGH, N.C., Feb. 23, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, continues our expansion across the burgeoning Asia-Pacific region with the recent opening of an office in Singapore. The office will serve as PRA's central clinical operations location for the region, strengthening the quality and timeliness of our deliverables to sponsors.

The Singapore facility, conveniently located in the heart of the city-state, will provide monitoring, project management, safety reporting, feasibility and other services.

"Building our capability across the region with the center in Singapore permits our sponsors to experience a wider range of services and expertise," said Helen Neal, PRA's Director of Clinical Operations for Asia-Pacific. "This location provides our teams with access to experts and resources within their time zone, positively impacting our speed and quality of delivery on projects."

Geographically renowned as the region's pharmaceutical and biomedical center, Singapore is the ideal location from which to deliver centralized study support to the region. This city-state serves as an excellent logistics hub with high fluency rates in English, and its government strongly promotes and encourages CROs to conduct cutting-edge clinical research.

"Opening a Singapore office for PRA is an exciting and significant milestone in the company's evolution and is evidence that PRA acknowledges and embraces the full potential that the Asia-Pacific region can bring to the global business going forward," said Ms. Neal.

PRA has been strategically expanding our Asia-Pacific operations since 2000. In addition to Singapore, PRA operates in eight other countries within the region: Korea, Taiwan, China, Hong Kong, Thailand, Australia, New Zealand, and India.

About PRA   

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stevenage Bioscience Catalyst Opens With Exciting Year Ahead
2. Alchem International Opens Sales and Marketing Office in the U.S.
3. CoreLab Partners Opens Office in Tokyo, Japan
4. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
5. Golden Seeds Opens Office in PLSG Incubator
6. MIABE standard opens up new opportunities in drug discovery
7. Medical Malpractice Insurance Company- Healthcare Providers Insurance Exchange (HPIX) has Expanded its Presence in New Jersey, Opens New Office
8. "Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use
9. New England Biolabs Opens New Subsidiary Office in France
10. New beamline at MAX II opens for research
11. Discovery opens the door to electricity from microbes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member. David ... ( North America ), will serve as ... "We,re pleased to have Ipsen and Dr. Cox ... Leonard . "We welcome their insights in helping us ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for Parkinson’s ... study published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation ... produce more neural cells. , Strategies involving transplantation of these cells into ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished life ... operations. , Avomeen is a leader in a wide range of services ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a ... ) and the US National Institutes of Health. Continue ... ... ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
Breaking Biology News(10 mins):